glp 1 2024 The promise and peril of GLP-1 agonists: What we do (and don't) know as of August Paving the way for expanded

Polonsky, PhD, CDCES & Susan Guzman, PhD (Behavioral Diabetes Institute) that reveals psychosocial forces behind diabetes self-management tools to break through resistance and inspire change

This often allows higher lifetime value per patient One time program fee for a 12 week intensive with coaching plus check ins Example scenario: If you charge 150 per month for coaching and enroll 50 patients through a partner clinic, that is 7,500 per month in recurring revenue without clinic overhead

We therefore propose that GLP-1(936) plays an important and previously unrecognised role as a systemic inhibitor of glucagon secretion (but not the only one)

GLP-1 agonists include (not all are available in Australia): semaglutide (brand names Ozempic, Wegovy, Rybelsus), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide (Byetta, Bydureon) and lixisenatide (Lyxumia, Adlyxin)

Other studies have so far only taken place in animal models